I just got this article via an aggregated email feed from
Uro Today, presenting links to reports from the 2018 GU ASCO conference in Chicago. As usual, anything mentioning treatments for high-risk cases catches my attention. At least one of our active forum members had this treatment, if I recall correctly.
The ASCO report described a Finnish phase III randomized controlled trial involving 376 cases:
This randomized trial evaluated if six courses of docetaxel improve biochemical disease-free survival (BDFS) after radical radiotherapy for intermediate or high-risk prostate cancer.In short, adjuvent Docetaxel didn't seem to be effective in this particular study, though it has been in other settings.
Just sharing for general info. Maybe one of the smart folks will comment.
ASCO 2018: SPCG-13: A Randomized Phase III Trial Between Adjuvant Docetaxel and Surveillance after Radical Radiotherapy for Intermediate and High-Risk Prostate CancerFrom the article:
Kellokumpu-Lehtinen concluded with several take-home messages for SPCG-13:
Adjuvant docetaxel without prednisone did not improve BDFS after radical radiotherapy with ADT for intermediate or high-risk prostate cancer
Biochemical progression was lower than expected at five years in both arms of the trial
Docetaxel has proven to be effective in other prostate cancer disease states, but why it was not significant in the adjuvant setting deserves future preclinical and clinical focus